The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending mirikizumab (Omvoh) for adults with moderately to severely active Crohn’s disease who have not responded to previous biological treatment or cannot tolerate it.
The decision comes less than two months after the Medicines and Healthcare products Regulatory Agency granted marketing authorisation for mirikizumab in the UK. It will be available to eligible patients in England within 30 days of publication of the final guidance and within 60 days in Wales…
